Prognostic Value of Peripheral Blood T Lymphocyte Subsets in Clear Cell Renal Cell Carcinoma

Overview

Journal Transl Androl Urol

Date 2021 Feb 3

PMID 33532321

Citations 6

Authors

Yihong Zhou

Dong Jiang

Xi Chu

Wenjie Cheng

Shuchang Huang

Jinhua Wang

Hao Zhang

Min Liu

Yuxin Tang

Yingbo Dai

Affiliations

Soon will be listed here.

Abstract

Background: To date, few studies have evaluated the role of peripheral blood T lymphocyte subsets in patients with clear cell renal cell carcinoma (ccRCC). Here we measured the levels of peripheral blood T lymphocyte subsets and evaluated its prognostic value in ccRCC.

Methods: Data from 122 patients with RCC from January 2018 to January 2020 were collected. Preoperative peripheral blood T lymphocyte subsets and medical records were analyzed. Kaplan-Meier cures and log rank test were used for analyzing overall survival (OS). Univariate and multivariate survival analyses were underwent by performing the Cox proportional hazards models. Correlations were tested by Pearson's correlation analysis.

Results: Of 122 patients, a total of 80 ccRCC patients was enrolled. Patients with low CD3 T cells and low CD4/CD8 ratio displayed a worse OS than patients with high CD3 T cells and high CD4/CD8 ratio (P=0.029 and 0.002, respectively). Multivariate analyses showed CD3 T cells and CD4/CD8 ratio were independent predictive factors for the OS (HR: 0.295, 95% CI, 0.091-0.956; P=0.042 and HR: 0.244, 95% CI, 0.065-0.920; P=0.037, respectively). Moreover, NLR negatively correlated with both levels of CD3 T cells and CD4/CD8 ratio (P<0.001, r=-0.398 and P=0.012, r=-0.280, respectively).

Conclusions: The findings of our study suggest that preoperative CD3 T cells and CD4/CD8 ratio in peripheral blood are independent predictors for patients with ccRCC.

Citing Articles

Evaluation of the clinical significance of lymphocyte subsets and myeloid suppressor cells in patients with renal carcinoma.

Li Y, Wu Z, Ni C, Li Y, Wang P Discov Oncol. 2024; 15(1):512.

PMID: 39347882 PMC: 11442913. DOI: 10.1007/s12672-024-01405-2.

Low Levels of Natural Killer Cell in Newly Diagnosed Myelodysplastic Syndromes Patients May Confer Poor Prognosis: A Retrospective Cohort Study.

Gong S, Shi C Cancer Manag Res. 2024; 16:753-760.

PMID: 38974093 PMC: 11227877. DOI: 10.2147/CMAR.S469393.

Effect of immune-modulating metronomic capecitabine as an adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma.

He Q, Luo X, Liu L, Zhao C, Li Z, Jin F BMC Immunol. 2024; 25(1):28.

PMID: 38710996 PMC: 11071185. DOI: 10.1186/s12865-024-00621-3.

Low Pretreatment CD4:CD8 T Cell Ratios and CD39CD73CD19 B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma.

Turner R, Guy T, Geraghty N, Splitt A, Watson D, Brungs D Int J Mol Sci. 2023; 24(16).

PMID: 37628721 PMC: 10454544. DOI: 10.3390/ijms241612538.

Analysis of Risk Factors for Early Progression of Prostate Cancer After Initial Endocrine Therapy.

Hu B, Shu F, Liu Y, Zhu J, Wang H, Xie N J Cancer. 2023; 14(4):519-531.

PMID: 37057284 PMC: 10088537. DOI: 10.7150/jca.81513.

References

Huszno J, Kolosza Z, Mrochem-Kwarciak J, Rutkowski T, Skladowski K . The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma. Oncology. 2019; 97(1):7-17. DOI: 10.1159/000498943. View

Ruhle P, Fietkau R, Gaipl U, Frey B . Development of a Modular Assay for Detailed Immunophenotyping of Peripheral Human Whole Blood Samples by Multicolor Flow Cytometry. Int J Mol Sci. 2016; 17(8). PMC: 5000713. DOI: 10.3390/ijms17081316. View

Kawashima A, Kanazawa T, Kidani Y, Yoshida T, Hirata M, Nishida K . Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma. Sci Rep. 2020; 10(1):6220. PMC: 7148296. DOI: 10.1038/s41598-020-63060-1. View

De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S . Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. Clin Cancer Res. 2019; 25(13):3839-3846. DOI: 10.1158/1078-0432.CCR-18-3661. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Capitanio U, Bensalah K, Bex A, Boorjian S, Bray F, Coleman J . Epidemiology of Renal Cell Carcinoma. Eur Urol. 2018; 75(1):74-84. PMC: 8397918. DOI: 10.1016/j.eururo.2018.08.036. View

Qiao G, Wang X, Zhou X, Morse M, Wu J, Wang S . Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors. Int J Hyperthermia. 2019; 36(sup1):74-82. DOI: 10.1080/02656736.2019.1647350. View

Mano R, Flynn J, Blum K, Silagy A, DiNatale R, Marcon J . The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. Urol Oncol. 2019; 37(12):916-923. PMC: 7224592. DOI: 10.1016/j.urolonc.2019.09.006. View

Pan Q, Wang L, Chai S, Zhang H, Li B . The immune infiltration in clear cell Renal Cell Carcinoma and their clinical implications: A study based on TCGA and GEO databases. J Cancer. 2020; 11(11):3207-3215. PMC: 7097965. DOI: 10.7150/jca.37285. View

10.

Wang X, Wu D, Chen W, Liu J, Ju Y . Impact of radiotherapy on immunological parameters, levels of inflammatory factors, and clinical prognosis in patients with esophageal cancer. J Radiat Res. 2019; 60(3):353-363. PMC: 6530619. DOI: 10.1093/jrr/rrz006. View

11.

Xiong Y, Neskey D, Horton J, Paulos C, Knochelmann H, Armeson K . Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma. BMC Cancer. 2020; 20(1):229. PMC: 7076935. DOI: 10.1186/s12885-020-06726-3. View

12.

Karakhanova S, Ryschich E, Mosl B, Harig S, Jager D, Schmidt J . Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Br J Cancer. 2015; 112(6):1027-36. PMC: 4366903. DOI: 10.1038/bjc.2015.72. View

13.

Stenzel P, Schindeldecker M, Tagscherer K, Foersch S, Herpel E, Hohenfellner M . Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma. Transl Oncol. 2019; 13(2):336-345. PMC: 7031108. DOI: 10.1016/j.tranon.2019.11.002. View

14.

Luo Z, Wang Y, Lou Y, Cao C, Hubbard R, Xu N . Unfavorable clinical implications of peripheral blood CD44+ and CD54+ lymphocytes in patients with lung cancer undergoing chemotherapy. Int J Biol Markers. 2017; 33(2):208-214. DOI: 10.5301/ijbm.5000309. View

15.

Mendiratta P, Rini B, Ornstein M . Emerging immunotherapy in advanced renal cell carcinoma. Urol Oncol. 2017; 35(12):687-693. DOI: 10.1016/j.urolonc.2017.08.011. View

16.

Xu W, Atkins M, Mcdermott D . Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol. 2020; 17(3):137-150. DOI: 10.1038/s41585-020-0282-3. View

17.

Ishihara H, Tachibana H, Takagi T, Kondo T, Fukuda H, Yoshida K . Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. Target Oncol. 2019; 14(4):453-463. DOI: 10.1007/s11523-019-00660-6. View

18.

Waki K, Kawano K, Tsuda N, Komatsu N, Yamada A . CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients. Cancer Sci. 2020; 111(4):1124-1131. PMC: 7156874. DOI: 10.1111/cas.14349. View

19.

Lee H, Shin D, Lee Y, Lee S, Hwang C, Kim A . PD-L1 expression and infiltration by CD4 and FoxP3 T cells are increased in Xp11 translocation renal cell carcinoma and indicate poor prognosis. Histopathology. 2019; 76(5):714-721. DOI: 10.1111/his.14047. View

20.

An N, Wang H, Jia W, Jing W, Liu C, Zhu H . The prognostic role of circulating CD8 T cell proliferation in patients with untreated extensive stage small cell lung cancer. J Transl Med. 2019; 17(1):402. PMC: 6892179. DOI: 10.1186/s12967-019-02160-7. View